The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 351:717-719 August 12, 2004 Number 7
NextNext

Triple-Nucleoside Regimens versus Efavirenz

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Gulick, R. M.
-PubMed Citation
To the Editor: Gulick et al. (April 29 issue)1 show that for the initial treatment of human immunodeficiency virus type 1 (HIV-1) infection, a triple-nucleoside combination of abacavir, zidovudine, and lamivudine is inferior to an efavirenz-based regimen. Among patients in the triple-nucleoside group who had a viral load of less than 50 copies per milliliter, there was also a trend toward a shorter time to virologic rebound. The convenience of the regimen of the coformulated three nucleosides can be an important component of its efficacy,2 especially over the long term, when adherence tends to decline; the double-blind design of this . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.